Graphene Investments SAS Purchases 3,400 Shares of IQVIA Holdings Inc. $IQV

Graphene Investments SAS increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 22.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,400 shares of the medical research company’s stock after buying an additional 3,400 shares during the period. Graphene Investments SAS’s holdings in IQVIA were worth $2,900,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Verdence Capital Advisors LLC bought a new stake in shares of IQVIA during the 2nd quarter worth $3,612,000. Patton Fund Management Inc. acquired a new position in IQVIA during the 2nd quarter worth $231,000. Heritage Investors Management Corp grew its position in shares of IQVIA by 10.5% in the second quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after purchasing an additional 9,909 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after purchasing an additional 566 shares during the period. Finally, Nordea Investment Management AB boosted its stake in IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of research analyst reports. Mizuho upped their price target on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Stifel Nicolaus boosted their price objective on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Monday. Citigroup boosted their price target on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $239.94.

IQVIA Stock Performance

IQV stock opened at $210.19 on Thursday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $225.91. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a market cap of $35.80 billion, a P/E ratio of 28.83, a price-to-earnings-growth ratio of 2.36 and a beta of 1.34. The business’s fifty day moving average is $198.53 and its 200-day moving average is $175.34.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the company posted $2.84 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.